Zura Bio Limited (NASDAQ:ZURA) Given Consensus Rating of “Buy” by Analysts

Shares of Zura Bio Limited (NASDAQ:ZURA) have received a consensus recommendation of “Buy” from the six brokerages that are covering the firm, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $19.75.

Several research firms recently issued reports on ZURA. Cantor Fitzgerald began coverage on shares of Zura Bio in a report on Wednesday, June 12th. They set an “overweight” rating for the company. Oppenheimer raised their price target on Zura Bio from $16.00 to $21.00 and gave the company an “outperform” rating in a report on Friday, May 10th. Finally, Piper Sandler initiated coverage on Zura Bio in a research note on Friday, May 3rd. They issued an “overweight” rating and a $26.00 price target on the stock.

Insider Activity

In other news, Director Van Amstel Arnout Ploos bought 80,000 shares of the stock in a transaction on Friday, May 17th. The stock was purchased at an average cost of $6.20 per share, with a total value of $496,000.00. Following the purchase, the director now owns 100,000 shares of the company’s stock, valued at $620,000. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 15.80% of the company’s stock.

Institutional Trading of Zura Bio

A number of hedge funds have recently added to or reduced their stakes in ZURA. Affinity Asset Advisors LLC acquired a new position in shares of Zura Bio during the 1st quarter valued at about $1,157,000. Armistice Capital LLC raised its stake in Zura Bio by 15.4% during the fourth quarter. Armistice Capital LLC now owns 1,824,000 shares of the company’s stock worth $8,518,000 after purchasing an additional 244,000 shares during the period. Finally, Forefront Analytics LLC boosted its holdings in shares of Zura Bio by 46.8% in the 4th quarter. Forefront Analytics LLC now owns 21,229 shares of the company’s stock valued at $99,000 after purchasing an additional 6,765 shares during the last quarter. 61.14% of the stock is owned by institutional investors and hedge funds.

Zura Bio Stock Up 7.6 %

Zura Bio stock opened at $3.84 on Wednesday. The stock has a 50 day moving average of $4.17 and a two-hundred day moving average of $3.78. Zura Bio has a twelve month low of $2.00 and a twelve month high of $7.63.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.21. Analysts predict that Zura Bio will post -0.53 earnings per share for the current fiscal year.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.